[Treatment with CEP (CCNU, VP-16 and prednimustine) in Hodgkin's disease resistant to CVPP and ABVD. Results in 21 patients].
Cervantes
F
F
Reverter
J C
JC
Bladé
J
J
Montserrat
E
E
Rozman
C
C
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin; D002648:Child; D003606:Dacarbazine; D004317:Doxorubicin; D004341:Drug Evaluation; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D011238:Prednimustine / Q000008:administration & dosage; D011241:Prednisone; D011344:Procarbazine; D014747:Vinblastine; D014750:Vincristine
D001761:Bleomycin; D011344:Procarbazine; D014750:Vincristine; D014747:Vinblastine; D005047:Etoposide; D008130:Lomustine; D003606:Dacarbazine; D004317:Doxorubicin; D011238:Prednimustine; D011241:Prednisone
Tratamiento con CEP (CCNU, VP-16 y prednimustina) de la enfermedad de Hodgkin resistente a CVPP y ABVD. Resultados en 21 pacientes.